Washington D.C. – A growing body of research is prompting concern among medical professionals regarding potential nutritional deficiencies in patients taking GLP-1 receptor agonist medications, commonly prescribed for weight loss and management of type 2 diabetes. A systematic review published this month by the Hunter Medical Research Institute (HMRI) in Australia found that clinical trials of these medications rarely assess or report on dietary intake or nutrient levels, raising the possibility of long-term health risks.
The medications, including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro), work by suppressing appetite, leading to significant weight loss. Yet, researchers argue that this appetite suppression may inadvertently lead to inadequate intake of essential vitamins and minerals. The HMRI review, which examined data from 41 randomized controlled trials encompassing over 50,000 participants, discovered that only two studies assessed dietary intake.
“Very little is known about the exact changes these medications have on what people actually eat, whether vitamin and mineral intakes are adequate, and whether weight-loss achieved through medication also supports optimal nutrition-related health and wellbeing in the long-term,” researchers at HMRI stated in a February 3, 2026, report. The findings, published in the journal Food and Nutrition Research, highlight a “critical blind spot” in current research protocols.
One particular concern raised by the review is the potential for scurvy, a disease caused by vitamin C deficiency. Historically known as “pirate’s disease” due to its prevalence among sailors with limited access to fresh produce, scurvy manifests with symptoms including anemia, bruising, bleeding gums, and impaired wound healing. Although researchers emphasize that cases of scurvy linked to GLP-1 medications appear rare, they caution that symptoms of nutrient deficiencies can overlap with common side effects of the drugs, such as fatigue and nausea, making early detection difficult.
The HMRI review also points to the risk of other deficiencies, including iron deficiency leading to anemia, and low levels of B vitamins, which can contribute to neurological problems. A related study published in PubMed on January 5, 2026, echoed these concerns, noting the lack of dietary assessment in the vast majority of GLP-1/GIP RA medication trials. The study found that of 43 articles reviewed from 41 unique trials, only two assessed or reported dietary intake.
Experts are now urging physicians to proactively monitor patients’ nutritional status while they are on GLP-1 medications. Recommendations include working with registered dietitians to ensure that even reduced meal sizes are nutritionally dense, and considering screening for deficiencies before initiating treatment. A fact check conducted by TNND on February 20, 2026, confirmed the findings of the HMRI review and the potential for vitamin deficiencies.
Researchers stress that the findings are not a call to halt the use of GLP-1 medications, which have proven effective for weight loss and metabolic health. However, they emphasize the need for a more holistic approach to patient care that prioritizes nutritional monitoring and support. Future clinical trials, they argue, should incorporate validated dietary assessment tools and transparent reporting of food and nutrient intakes.
